A phase II study of ONTAK (denileukin diftitox, DABIL-2) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia [CLL]
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Sep 2005 New trial record.